What does the most recent data indicate about short interest in the top biotech stocks? The short answer, today’s article notes, is that “short interest in most of these selected biotech stocks increased” compared with the previous report. For the specifics on short interest in each of the top biotech stocks, from Alexion to Vertex, CLICK HERE.
“Call it what you will, but I think traders who’ve dug into the biotech space initially came for the COVID, then figured out there’s far more to this industry than coronavirus treatments,” remarks the author of today’s article. They proceed to examine three biotech penny stocks that, be it due to COVID-related or COVID-unrelated factors, may be worth considering buying – or bypassing. For these three biotech penny stocks – two of which are up by triple digits year-to-date – CLICK HERE.
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes clinical with several of the therapies in its pipeline. More specifically, the company “is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9” – and Goldman Sachs rates the stock as a “Buy”. For more on this biotech, its pipeline of therapies, and the investment thesis for it, CLICK HERE.
The biotechnology sector’s outperformance amid the pandemic has led some analysts to refer to this time as the “golden period of biotechnology”. When it comes to the best biotech stock picks, the author of today’s article identifies three parameters to consider: “hedge fund and institutional investor sentiment towards the stock, market performance, quarterly results and competitive advantage.” With this in mind, he highlights three biotech stocks that appear poised for massive growth going forward – and, not surprisingly, all three are participants in the race for a COVID-19 vaccine. For more, CLICK HERE.
“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the Chinese biotech highlighted in today’s article, whose “steadfast mission [is] to become a global oncology business, and revolutionize cancer treatment by creating a portfolio of drugs aimed at preventing the disease from multiple angles through combining different therapies.” For more on this company – whose shares are dual-listed in the UK and on the Nasdaq, and which Goldman Sachs analysts rate as a Buy – CLICK HERE.
A biopharmaceutical company focused on addressing unmet needs in the fields of severe burns and other hard-to-heal wounds and a second biopharmaceutical company focused on developing novel solutions for the treatment of specialty cancers and urological diseases make up two of the three stocks highlighted in today’s article where analysts at Oppenheimer see triple-digit upside potential. For more on these three stocks, CLICK HERE.
The clinical-stage biotech highlighted in today’s article – operating in the hot immuno-oncology sector – has both long-term and short-term bull cases to be made for it, with the author finding the short-term bull thesis – that the stock is currently undervalued following a major partnership deal – to be particularly compelling. Here’s some of what he has to say: “Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future looks bright for [this company]”. For more, CLICK HERE.
“This is a market that favors stock picking over market timing and macro analysis,” advises the author of today’s article, who argues that “The business media is blind to what is going on under the surface of the market because it focuses on the indices and a small group of big-cap names and talks to billion-dollar hedge fund managers who depend on macro predictions.” Why does he believe that the recent pullbacks are not a cause for concern – and when does he believe is the time to be concerned? CLICK HERE.
“One method of finding great stocks is to hunt down clinical stage companies with potential new treatment methods for diseases and ailments that affect large numbers of people,” advises the author of today’s article. As such, she proceeds to highlight two clinical-stage biotechs whose novel approaches to delivering vaccines (including a COVID-19 vaccine candidate) and treating genetic diseases, respectively, could bring big rewards to investors with the right risk tolerance. For these two potentially game-changing biotech stocks, CLICK HERE.
Of the most popular stocks on the Robinhood trading app, which boast the highest analyst ratings? Today’s article identifies the five most popular Robinhood stocks that “have a 92% ‘buy’ rating or better among the analysts who cover them” – a group that includes two very small biotech firms and a small-cap cannabis company. For these five stocks that are tops with both Robinhood users and analysts, CLICK HERE.